What Has Been the Growth Trajectory for the HER2-Positive Breast Cancer Market in Recent Years?
The her2-positive breast cancer market has seen considerable growth due to a variety of factors.
• In recent times, there has been a significant growth in the market size for HER2-positive breast cancer. The market forecast predicts an increase from $10.21 billion in 2024 to $10.96 billion in 2025, reflecting a compound annual growth rate (CAGR) of 7.34%.
The previous growth can be credited to factors such as the rise in early detection and diagnosis, heightened awareness about HER2-positive subtypes, increased investment in research and development, broader acceptance of precision medicine, and enhanced emphasis on bettering patient outcomes.
How Does the Forecast Look for the HER2-Positive Breast Cancer Market?
The her2-positive breast cancer market is expected to maintain its strong growth trajectory in upcoming years.
• In the coming years, a considerable surge is expected in the HER2-positive breast cancer market, which is projected to reach $14.41 billion in 2029, growing at a yearly compound rate of 7.08%.
This predicted expansion can be attributed to several factors, such as the increasing need for liquid biopsy for non-invasive monitoring, growing adoption of combined treatments, heightened emphasis on immunotherapies and novel drug formulas. Enhanced usage of liquid biopsy techniques for non-invasive monitoring, and a rise in the number of dedicated cancer treatment facilities also contribute to this growth. The forecast period will also witness major developments like advancements in targeted therapies, innovative drug formulations, and breakthroughs in immunotherapy methods. Additionally, the creation of new HER2-specific therapies and advancements in biomarkers for improved patient stratification will mark essential trends.
What Are The Essential Drivers Behind The Growth Of The HER2-Positive Breast Cancer Market?
The robust uptake of immunotherapy is anticipated to boost the expansion of the HER2-positive breast cancer market in the future. Immunotherapy is a medicinal treatment that augments or alters the immune system's inherent ability to combat illnesses such as cancer, infections, and autoimmune disorders. Its adoption is credited to its potential to amplify the immune system's capacity to detect and destroy cancer cells, offering superior efficacy and less adverse effects compared to standard treatments. In the context of HER2-positive breast cancer, immunotherapy enhances the body's immune system's capability to recognize and assail HER2-overexpressing cancer cells, thereby improving the results of treatment and lowering the risk of reoccurrence. For example, in July 2023, the American Association for Cancer Research, a US-based entity, reported that the FDA had approved 11 immune checkpoint inhibitors (ICIs), with a minimum of one ICI approved for the treatment of 20 distinct cancer types and for any solid tumor displaying specific molecular characteristics in 2023. Consequently, the robust uptake of immunotherapy is propelling the expansion of the HER2-positive breast cancer market.
How Are The Segments Defined Within The Global HER2-Positive Breast Cancer Market?
The HER2-positive breast cancer market covered in this report is segmented –
1) By Treatment Type: Targeted Therapy, Chemotherapy, Endocrine Therapy, Immunotherapy, Other Treatment Types
2) By Route Of Administration: Parenteral, Oral, Other Route Of Administrations
3) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy
4) By End User: Hospitals, Homecare, Specialty Clinics, Other End User
Subsegments:
1) By Targeted Therapy: HER2 Inhibitors (Trastuzumab, Pertuzumab), Tyrosine Kinase Inhibitors (TKIs), Antibody-Drug Conjugates (ADC), Small Molecule Inhibitors
2) By Chemotherapy: Anthracycline-based Chemotherapy, Taxane-based Chemotherapy, Platinum-based Chemotherapy, Combination Chemotherapy Regimens
3) By Endocrine Therapy: Selective Estrogen Receptor Modulators (SERMs), Aromatase Inhibitors, Estrogen Receptor Antagonists, Estrogen Deprivation Therapy
4) By Immunotherapy: Immune Checkpoint Inhibitors (PD-1/PD-L1 Inhibitors), Monoclonal Antibodies for Immune Modulation, Cancer Vaccines
5) By Other Treatment Types: Radiation Therapy, Stem Cell Therapy, Hyperthermia Treatment, Gene Therapy, Surgical Interventions (Mastectomy, Breast Conserving Surgery)
Pre-Book The HER2-Positive Breast Cancer Global Market Report 2025 Report For Swift Delivery And Comprehensive Insights:
How Are New Trends Expected To Influence The Growth Of The HER2-Positive Breast Cancer Market?
Top-tier corporations in the HER2-positive breast cancer sector are concentrating their efforts on creating unique therapies like HER2-directed antibody-drug conjugates (ADCs), in order to streamline and optimize patient treatment processes. These HER2-targeted ADCs are specialized cancer treatments that tie an antibody, which is specific to HER2, to a toxin, effectively delivering the medicine directly to the HER2-positive cancer cells, thus increasing treatment efficacy. For example, in January 2024, AstraZeneca India Pharma Ltd., a biopharmaceutical corporation based in India, launched an innovative therapy known as Trastuzumab deruxtecan. This novel treatment, a product of a joint effort between AstraZeneca and Daiichi Sankyo, is a HER2-targeted ADC that directs the cytotoxic drug to HER2-positive cancer cells, thus providing a more precise and effective treatment for patients.
Who Are the Key Players in the HER2-Positive Breast Cancer Market?
Major companies operating in the HER2-positive breast cancer market are include:
• Johnson & Johnson Services Inc.
• F. Hoffmann-La Roche AG
• Merck & Co. Inc.
• Bayer AG
• Sanofi S.A.
• AstraZeneca plc
• Novartis International AG
• GlaxoSmithKline plc
• Eli Lilly and Company
• Amgen Inc.
• Boehringer Ingelheim GmbH
• Daiichi Sankyo Co. Ltd.
• Incyte Corporation
• BioNTech SE
• MacroGenics Inc.
• CStone Pharmaceuticals Co. Ltd.
• Sorrento Therapeutics Inc.
• Syndax Pharmaceuticals Inc.
• Fate Therapeutics Inc.
• Ambrx Biopharma Inc.
What Is The Most Dominant Region In The HER2-Positive Breast Cancer Market?
North America was the largest region in the HER2- positive breast cancer market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the HER2-positive breast cancer market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
